Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- Check8 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1; no changes to page content or layout are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoChange DetectedUI and metadata updates are present, including a 'Show glossary' option, capitalization adjustments for 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and a revision indicator updated to v3.4.0. These changes do not alter core study content, endpoints, or results display.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedLocations section updated with numerous new trial sites across the US and internationally, including multiple states and countries. Several previously listed sites have been removed.SummaryDifference2%

- Check80 days agoChange DetectedThe page revision label was updated from v3.2.0 to v3.3.2, indicating a minor metadata update.SummaryDifference0.0%

- Check87 days agoChange DetectedRemoved the government funding lapse notice; no study content or endpoints were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.